Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials-Reference-Cited by-同舟云学术

Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials

Published:2023-11 Issue: Volume:37 Page:101763
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Nawaf Cayce^ORCID,Shiang Alexander^ORCID,Chauhan Pradeep S.,Chaudhuri Aadel A.,Agarwal Gautum,Smith Zachary L.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018;Cumberbatch;Eur. Urol.,2018

2. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis;Raitanen;Eur. Urol.,2002

3. Advanced liquid biopsy technologies for circulating biomarker detection;Soda;J. Mater. Chem. B,2019

4. Bladder cancer: a review;Lenis;JAMA,2020

5. Comprehensive molecular characterization of urothelial bladder carcinoma;Network;Nature,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to Chao Song’s Letter to the Editor re: Florus C. de Jong, Iris G. Iflé, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131–9;European Urology Open Science;2024-08

2. Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications;Cancers;2024-06-20

3. Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer;International Journal of Molecular Sciences;2023-11-21